

Bone&JointScience

Our Innovation in Focus

BIOSURE[◊] REGENESORB Interference Screw: Rapid bone ingrowth and tendon-bone healing at 12 weeks in an ovine anterior cruciate ligament reconstruction model.

John Watson¹; Nick Cotton, PhD²

1. Smith & Nephew, Inc., Baar, Switzerland

2. Smith & Nephew, Inc., Mansfield, Massachusetts, USA

1 Research goal

To measure bone ingrowth into BIOSURE[◊] REGENESORB Interference Screws and assess bone-tendon integration in an ovine anterior cruciate ligament (ACL) reconstruction model.¹

2 Type of evidence



3 Clinical relevance

- There has been a steady rise in ACL reconstruction procedures performed in recent decades, particularly in female patients and those younger than 20 or older than 40 years of age.²
- Globally, bioabsorbable interference screws are routinely used as fixation devices for reattaching soft tissue to bone in ACL reconstruction.³
- BIOSURE[◊] REGENESORB Interference Screws (Smith & Nephew, Inc.; **Figure 1**) have an open architecture, and six times more surface area for bone ingrowth than conventional solid interference screws.⁴ REGENESORB is an advanced biocomposite material that utilizes two osteoconductive components: calcium sulfate and beta-tricalcium phosphate (β-TCP). These materials aid in the bone healing process at both early (4–12 weeks) and late (up to 18 months) time points.^{5–8}


4 Key results

- At 12 weeks, the mean volume of bone restored within the open cannulation of the interference screws was 50% and 44% in the femoral and tibial tunnel sites, respectively (**Figure 2**).¹
- Tendon remodeling was observed within the tunnels, usually together with ossification and/or bone integration.¹

Figure 1: BIOSURE REGENESORB Interference Screw.



Figure 2: Bone ingrowth in the central cannulation of the BIOSURE REGENESORB Interference Screw at 12 weeks.¹



5 Important considerations

- Although encouraging, animal study outcomes do not necessarily correlate with human outcomes.

Background

ACL injuries have become increasingly common in recent decades as greater numbers of younger people participate in high-level sports and older individuals maintain active lifestyles for longer.² This has led to a corresponding rise in ACL reconstruction procedures performed, particularly in female patients and those younger than 20 or older than 40 years of age.² Global survey data indicate that bioresorbable interference screws are routinely used as fixation devices for reattaching soft tissue to bone during these procedures.³

The graft fixation point is vulnerable following ACL reconstruction. Therefore, achieving tendon integration with the bone is critical for providing fixation, stability, and long-term graft survival.⁹⁻¹¹ It is thought that obtaining a direct bone-tendon interface, without a fibrous intermediate layer, is only possible with an anatomic interference fixation and its ability to prevent micromovement.¹¹

The BIOSURE[®] REGENESORB Interference Screw (Smith & Nephew, Inc., Andover, MA, USA; **Figure 3**) has an open architecture for use for the reattachment of ligament, tendon, soft tissue, or bone-tendon-bone grafts. Micro-computed tomography (μ CT) analysis⁴ indicates that BIOSURE[®] REGENESORB has six-times the available surface area for bone ingrowth compared with conventional solid interference screws.*

REGENESORB is an advanced biocomposite material comprised of the co-polymer poly (l-lactide co-glycolide) combined with two components, calcium sulfate and β -TCP, which have different mechanisms of action but have each been demonstrated to be osteoconductive.⁵⁻⁸ β -TCP provides sustained bone formation over 18 months⁵ and acts primarily as a scaffold for enhancing bone formation.⁸ The REGENESORB material also delivers an early release of calcium¹² (**Figure 4**), which works in the early stages of bone healing (4–12 weeks)⁵ and is associated with increased levels of local growth factors.¹³ REGENESORB is designed to remain mechanically stable for a minimum of six months before being absorbed and replaced by bone within 24 months.¹⁴


Tendon-to-bone interface healing is important in the early 6- to 12-week post-operative period,^{10,11} which correlates with critical time points in post-ACL reconstruction rehabilitation protocols, such as achieving full weight bearing by eight to 10 weeks. The current study was undertaken to measure bone ingrowth into BIOSURE[®] REGENESORB Interference Screws and concurrent tendon integration after the critical 12-week implantation period in an ovine ACL reconstruction model.¹

*As compared with BioComposite (Arthrex, Inc.) and MILAGRO (DePuy Synthes Mitek Sports Medicine)

Figure 3:
BIOSURE[®] REGENESORB Interference Screw.



Figure 4:
Calcium release from a 6 x 25mm
BIOSURE[®] REGENESORB screw.¹²



Methods

- Twelve sheep underwent unilateral excisional ACL reconstruction. One animal was excluded due to tunnel breaching the medullary canal in the tibia, possibly compromising the implant security. This left 11 animals for which tibial and femoral samples were available for analysis.
- BIOSURE® REGENESORB Interference Screws (7 x 25mm) were implanted in both the femoral and tibial bone tunnels in this ovine model of ACL reconstruction. A digital extensor tendon was used as the replacement ligament.
- At 12-weeks post-implantation the animals were euthanized and the implants and surrounding tissue were harvested for analysis.
- Bone ingrowth into defined volumes of interest around the femoral and tibial screws was determined by μ CT. The percentage of bone in a defined volume adjacent to the implanted screws was also determined by μ CT.
- To evaluate bone and tendon integration, histological specimens of distal femur and proximal tibia were resin embedded and thick sections cut and ground using the EXAKT system. An observational assessment of the slides was performed and images captured to determine local bone reaction and inflammation at the implantation site.

Results

- At 12 weeks, the mean volume of new bone restored within the center cannulation of the interference screws was 50% (standard deviation (SD): ± 12) and 44% (SD: ± 11), in the femoral and tibial tunnel sites, respectively (Figure 5).
- Histological assessment confirmed bone growth into the screw threads/fenestrations, and through the center cannulation and threads/fenestrations adjacent to the tendon. An example of bone integration and ingrowth at 12 weeks appears in Figure 6.
- Evidence of the tendon graft was seen in all the tunnels with the exception of one specimen. Tendon remodeling was observed usually together with ossification and/or bone ingrowth (Figure 7).

Figure 5:

Mean bone volume restored in samples receiving BIOSURE® REGENESORB, as compared with normalized bone samples.¹





Figure 6:

Rapid bone integration and ingrowth in the central cannulation of the BIOSURE® REGENESORB Screw through the fenestrations.¹

Femur–Normal Anatomy



Bone Ingrowth at 12 Weeks





Figure 7:

Cross section of screw at 12 weeks. New bone formation within the screw and new bone surrounding and integrating with the graft on all surfaces.¹



Conclusions

At 12 weeks, the BIOSURE° REGENESORB Interference Screw facilitates bone-tendon integration and bone-screw attachment. The open architecture provides channels and open space, which allows for the formation of new bone. Histological and radiographic evidence from an ovine ACL reconstruction study at 12 weeks indicates that bone can penetrate through the implant and form direct attachment to the tendon surface abutting the BIOSURE° REGENESORB Interference Screw. To our knowledge, this is the first time circumferential tendon-bone healing has been demonstrated in combination with an advanced biocomposite material using an interference screw fixation in pre-clinical results. Although encouraging, animal study outcomes do not necessarily correlate with human outcomes.


References

1. Data on file at Smith and Nephew, report NCS250.
2. **Mall NA, Chalmers PN, Moric M, et al.** Incidence and trends of anterior cruciate ligament reconstruction in the United States. *Am J Sports Med.* 2014;42:2363–2370.
3. **Chechik O, Amar E, Khashan M, Lador R, Eyal G, Gold A.** An international survey on anterior cruciate ligament reconstruction practices. *Int Orthop.* 2013;37:201–206.
4. Data on file at Smith and Nephew, report 15005255. As compared with BioComposite (Arthrex, Inc.) and MILAGRO (DePuy Synthes Mitek Sports Medicine).
5. **Hak DJ.** The use of osteoconductive bone graft substitutes in orthopaedic trauma. *J Am Acad Orthop Surg.* 2007;15:525–536.
6. **Allison DC, Lindberg AW, Samimi B, Mirzayan R, Menendez LR.** A comparison of mineral bone graft substitutes for bone defects. *US Oncol Hematol.* 2011;7:38–49.
7. **Costantino PD, Friedman CD.** Synthetic bone graft substitutes. *Otolaryngol Clin North Am.* 1994;27:1037–1074.
8. **Ogose A, Hotta T, Kawashima H, et al.** Comparison of hydroxyapatite and beta tricalcium phosphate as bone substitutes after excision of bone tumors. *J Biomed Mater Res B Appl Biomater.* 2005;72:94–101.
9. **Pinczewski LA, Clingeleffer AJ, Otto DD, Bonar SF, Corry IS.** Integration of hamstring tendon graft with bone in reconstruction of the anterior cruciate ligament. *Arthroscopy.* 1997;13:641–643.
10. **Rodeo SA, Arnoczky SP, Torzilli PA.** Tendon-healing in a bone tunnel. A biomechanical and histological study in the dog. *J Bone Joint Surg Am.* 1993;75:1795–1803.
11. **Weiler A, Peine R, Pashmineh-Azar A, Abel C, Sudkamp NP, Hoffman RF.** Tendon healing in a bone tunnel. Part 1: Biomechanical results after biodegradable interference fit fixation in a model of anterior cruciate ligament reconstruction in sheep. *Arthroscopy.* 2002;18:113–123.
12. Data on file at Smith and Nephew, report ITR 3610.
13. **Walsh WR, Morberg P, Yu Y, et al.** Response of a calcium sulfate bone graft substitute in a confined cancellous defect. *Clin Orthop Relat Res.* 2003;406:228–236.
14. Data on file at Smith & Nephew, report No. 15000897.

Notes

A series of horizontal dotted lines for taking notes.

Disclaimer Great care has been taken to maintain the accuracy of the information contained in the publication. However, neither Smith & Nephew, nor the authors can be held responsible for errors or any consequences arising from the use of the information contained in this publication. The statements or opinions contained in editorials and articles in this journal are solely those of the authors thereof and not of Smith & Nephew. The products, procedures, and therapies described are only to be applied by certified and trained medical professionals in environments specially designed for such procedures. No suggested test or procedure should be carried out unless, in the reader's professional judgment, its risk is justified. Because of rapid advances in the medical sciences, we recommend that independent verification of diagnosis, drugs dosages, and operating methods should be made before any action is taken. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. Some of the products, names, instruments, treatments, logos, designs, etc. referred to in this journal are also protected by patents and trademarks or by other intellectual property protection laws even though specific reference to this fact is not always made in the text. Therefore, the appearance of a name, instrument, etc. without designation as proprietary is not to be construed as a representation by the publisher that it is in the public domain. This publication, including all parts thereof, is legally protected by copyright. Any use, exploitation or commercialization outside the narrow limits of copyrights legislation, without the publisher's consent, is illegal and liable to prosecution. This applies in particular to photostat reproduction, copying, scanning or duplication of any kind, translating, preparation of microfilms and electronic data processing and storage. Institutions' subscriptions allow to reproduce tables of content or prepare lists of articles including abstracts for internal circulation within the institutions concerned. Permission of the publisher is required for resale or distribution outside the institutions. Permission of the publisher is required for all other derivative works, including compilations and translations. Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. For inquiries contact the publisher at the address indicated.



Smith & Nephew Pty Ltd
Australia
T +61 2 9857 3999
F +61 2 9857 3900

Smith & Nephew Ltd
New Zealand
T +64 9 820 2840
F +64 9 820 2841

®Trademark of Smith & Nephew.
All Trademarks acknowledged.
©2016 Smith & Nephew
07391-anz V1 0320
SNI4836 REV0

Produced and published by the Scientific & Medical Affairs Department,
Smith & Nephew Orthopaedics AG.
Bone & Joint Science is available on Smith & Nephew's Education and Evidence website,
www.smith-nephew.com/education
Supporting healthcare professionals for over 150 years

www.smith-nephew.com/australia www.smith-nephew.com/newzealand